How should we appropriately classify low-risk uterine cervical cancer patients suitable for de-intensified treatment?

Article Oncology

Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)

Sue S. Yom et al.

Summary: Reducing radiation treatment dose in patients with good-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma (OPSCC) could potentially improve the quality of life. The study showed that reducing radiation dose could achieve disease control and survival rates equivalent to standard chemoradiation.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Why De-Intensification is not Possible in HPV-Associated Cervical Cancer

Brian T. Beaty et al.

SEMINARS IN RADIATION ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer

Ikumi Kuno et al.

Summary: In locally advanced cervical cancer, TP53 mutation, large tumor diameter, and non-HPV16/18 genotype were independently correlated with poor progression-free survival, despite receiving concurrent chemoradiotherapy.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

Richard Pötter et al.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Why not de-intensification for uterine cervical cancer?

Naoya Murakami et al.

Summary: In the management of cervical cancer, low-risk patients can achieve favorable local control with de-escalated treatment intensity. Factors such as tumor reduction ratio, tumor size, and total treatment time can be used to identify these low-risk patients.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Biology